Tissue-agnostic cancer drug pipeline grows, despite doubts

Overview of attention for news story in Nature Reviews Drug Discovery

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 7 public wall posts from 7 users.

https://www.nature.com/articles/nrd.2018.6.epdf?shared_access_token=mq4FtcS98GEWTW-At-OIfNRgN0jAjWel9jnR3ZoTv0Px4Db26HEP3Hz9ZzKdL…

Chipping away at the old organ-based disease paradigm in oncology. http://rdcu.be/J3GL

Chipping away at the old organ-based disease paradigm in oncology. http://rdcu.be/J3GL

Nature Reviews Drug Discovery: The FDA could soon approve the first drug developed explicitly for a tissue-agnostic cancer…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity, including 3 additional Facebook posts.